Bradycardia associated with ALK inhibitors in the treatment of non-small cell lung cancers: a systematic review and meta-analysis

被引：0
|
作者：
Zhou, S. [1 ]
Cirne, F. [1 ]
Kappel, C. [1 ]
El-Kadi, A. [1 ]
Ellis, P. [1 ]
Leong, D. P. [2 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
[2] Populat Hlth Res Inst, Hamilton, ON, Canada
来源：
EUROPEAN HEART JOURNAL | 2021年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2848 / 2848
页数：1
相关论文
共 50 条
  • [41] Association of Smoking Status with Efficacy of First-line Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancers: A Systematic Review and Meta-analysis
    Kim, Jinchul
    Ha, Hyerim
    Park, Jisun
    Cho, Jinhyun
    Lim, Joo Han
    Lee, Moon Hee
    JOURNAL OF CANCER, 2022, 13 (02): : 364 - 372
  • [42] Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis
    Irvine, Andrew F.
    Waise, Sara
    Green, Edward W.
    Stuart, Beth
    Thomas, Gareth J.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [43] Characterising cancer-associated fibroblast heterogeneity in non-small cell lung cancer: a systematic review and meta-analysis
    Andrew F. Irvine
    Sara Waise
    Edward W. Green
    Beth Stuart
    Gareth J. Thomas
    Scientific Reports, 11
  • [44] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Cruz, Barbara D.
    Barbosa, Mariana M.
    Torres, Lucas L.
    Azevedo, Pamela S.
    Silva, Vania E. A.
    Godman, Brian
    Alvares-Teodoro, Juliana
    ONCOLOGY AND THERAPY, 2021, 9 (02) : 505 - 524
  • [45] Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Barbara D. Cruz
    Mariana M. Barbosa
    Lucas L. Torres
    Pamela S. Azevedo
    Vânia E. A. Silva
    Brian Godman
    Juliana Alvares-Teodoro
    Oncology and Therapy, 2021, 9 : 505 - 524
  • [46] Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis
    Li, Feng
    Zhai, Suokai
    Lv, Zhuoheng
    Yuan, Ligong
    Wang, Shuaibo
    Jin, Donghui
    Yi, Hang
    Fu, Li
    Mao, Yousheng
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [47] Efficacy and safety of anaplastic lymphoma kinase inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis
    Peng, Tzu-Rong
    Liao, Pei-Fei
    Wu, Ta-Wei
    THORACIC CANCER, 2023, 14 (10) : 929 - 939
  • [48] Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis
    Abdelhamid, Arwa
    Tuminello, Stephanie
    Ivic-Pavlicic, Tara
    Flores, Raja
    Taioli, Emanuela
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (12) : 2427 - 2439
  • [49] Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer A systematic review and meta-analysis
    Zhou, Kenan
    Zhao, Shishun
    Guo, Wenlai
    Ding, Lei
    MEDICINE, 2020, 99 (03)
  • [50] The efficacy of nivolumab for the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials
    Bao, Ming
    Pan, Yue-Jiang
    Wang, Ran
    Li, Sheng-Long
    Liang, Jie
    Yung, Jun-Ming
    Luo, Jia
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01): : 153 - 161
12345